Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Esophageal Squamous Cell Carcinoma · Neoadjuvant Chemoimmunotherapy · Adjuvant Therapy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Shanghai chest hospital, Shanghai, Shanghai Municipality, China
Contact: Principal Investigator (Xufeng Guo, Ph.D)
Study leads
Changqing Pan
Study Chair
the International Committee of Medical Journal Editors